Based on the finding of a RET rearrangement, we treated the patient with cabozantinib (XL184), a nonselective RET inhibitor known to have antitumor activity in differentiated thyroid cancer (Cabanillas et al., 2014). Here, RET is linked to differentiated thyroid carcinoma.